State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
BMC Cancer. 2010 Oct 8;10:538. doi: 10.1186/1471-2407-10-538.
LATS2, which encodes a novel serine/threonine kinase, is known to be important in centrosome duplication and in the maintenance of genomic stability. Recently, a potential role for LATS2 in cancer has been reported. In breast cancer and acute lymphoblastic leukemia (ALL), LATS2 mRNA is downregulated and has been suggested to be a tumor suppressor. However, the role of LATS2 in nasopharyngeal carcinoma has not been investigated. In this study, we aimed to investigate the expression pattern of LATS2 and its clinicopathological involvement in nasopharyngeal carcinoma to understand its effect on cell survival.
Using quantitative real time PCR and immunoblotting, the expression of LATS2 was detected in nasopharyngeal carcinoma cell lines and in the immortalized nasopharyngeal epithelial cell line NP69. Using immunohistochemistry, we analyzed LATS2 protein expression in 220 nasopharyngeal carcinoma cases. The association of LATS2 protein expression with the clinicopathological characteristics and the prognosis of nasopharyngeal carcinoma were subsequently assessed. Using methylation specific PCR, we detected the methylation status of the LATS2 promoter. RNA interference was performed by transfecting siRNA to specifically knock down LATS2 expression in 5-8F and CNE2.
LATS2 protein was detected in 178 of 220 (80.91%) cases of nasopharyngeal carcinoma. LATS2 overexpression was a significant, independent prognosis predictor (P = 0.037) in nasopharyngeal carcinoma patients. Methylation specific PCR revealed that 36.7% (11/30) of nasopharyngeal carcinoma tissues and all of the chronic nasopharyngeal inflammation samples were methylated. Functional studies showed that the suppression of LATS2 expression in nasopharyngeal carcinoma (5-8F and CNE2) cell lines by using specific small interfering (siRNA) resulted in the inhibition of growth, induction of apoptosis and S-phase cell cycle increase. Overexpression of LATS2 in NP69 stimulated cell proliferation.
Our results indicate that LATS2 might play a role in the tumorigenesis of nasopharyngeal carcinoma by promoting the growth of nasopharyngeal carcinoma cells. Transfection with specific siRNA might be feasible for the inhibition of growth, induction of apoptosis and S phase increase in nasopharyngeal carcinoma.
编码一种新型丝氨酸/苏氨酸激酶的 LATS2 已知在中心体复制和维持基因组稳定性方面很重要。最近,有报道称 LATS2 在癌症中可能发挥作用。在乳腺癌和急性淋巴细胞白血病(ALL)中,LATS2mRNA 下调,并被认为是一种肿瘤抑制因子。然而,LATS2 在鼻咽癌中的作用尚未得到研究。在这项研究中,我们旨在研究 LATS2 的表达模式及其在鼻咽癌中的临床病理相关性,以了解其对细胞存活的影响。
使用定量实时 PCR 和免疫印迹法检测鼻咽癌细胞系和永生化鼻咽上皮细胞系 NP69 中 LATS2 的表达。使用免疫组织化学方法分析 220 例鼻咽癌病例中 LATS2 蛋白的表达。随后评估 LATS2 蛋白表达与鼻咽癌临床病理特征和预后的相关性。使用甲基化特异性 PCR 检测 LATS2 启动子的甲基化状态。通过转染 siRNA 特异性敲低 5-8F 和 CNE2 中的 LATS2 表达来进行 RNA 干扰。
在 220 例鼻咽癌病例中,检测到 178 例(80.91%)LATS2 蛋白。LATS2 过表达是鼻咽癌患者独立的预后预测因子(P=0.037)。甲基化特异性 PCR 显示,36.7%(11/30)的鼻咽癌组织和所有慢性鼻咽炎症样本均发生甲基化。功能研究表明,使用特异性小干扰(siRNA)抑制鼻咽癌(5-8F 和 CNE2)细胞系中的 LATS2 表达可抑制生长、诱导凋亡和 S 期细胞周期增加。NP69 中 LATS2 的过表达可刺激细胞增殖。
我们的研究结果表明,LATS2 通过促进鼻咽癌细胞的生长可能在鼻咽癌的发生中发挥作用。用特异性 siRNA 转染可能可用于抑制鼻咽癌的生长、诱导凋亡和 S 期增加。